Starting April 1, 2026, the cost of essential medicines in India—including painkillers, antibiotics, and anti-infectives—will see a slight increase. While the hike is small, it impacts a wide range of commonly used drugs.
Change 1: Prices to Rise by Around 0.6%
The government has approved a price increase of about 0.6–0.65% on essential medicines.
- This applies to medicines listed under the National List of Essential Medicines (NLEM)
- The increase is uniform and regulated, not arbitrary
Compared to previous years, this is a very marginal hike.
Change 2: Based on Wholesale Price Index (WPI)
The price revision is linked to inflation, specifically the Wholesale Price Index (WPI).
- WPI rose by about 0.65% in 2025 compared to 2024
- As per policy, drug prices can be revised annually in line with WPI
This ensures prices move in sync with economic conditions and input costs.
Change 3: Over 1,000 Essential Medicines Affected
The hike will impact more than 1,000 essential drugs, including:
- Paracetamol (pain relief)
- Antibiotics like azithromycin
- Anti-infectives and vitamins
- Medicines for anemia and other common conditions
These are widely used medicines, meaning the change will affect almost every household.
Change 4: Price Increase Allowed Without Approval
Pharmaceutical companies are allowed to increase prices automatically based on WPI.
- No prior government approval is required
- This is permitted under the Drug Price Control Order (DPCO)
However, the increase is capped and tightly regulated.
Change 5: Industry Still Under Pressure
Despite the hike, pharma companies are facing rising costs:
- Raw materials (APIs) up by 30–35%
- Packaging materials up by ~40%
- Some drug inputs like paracetamol up 25%+
Industry experts say this small hike barely offsets rising costs.
What It Means for Consumers
- The increase is minimal, so most people may not notice a big difference
- However, for long-term treatments, costs may add up slightly over time
- Essential medicines remain regulated and affordable overall
Bigger Picture: Balancing Affordability & Sustainability
This annual revision reflects a balancing act:
- Keep medicines affordable for consumers
- Allow pharma companies to cope with rising costs
The government ensures hikes remain controlled and predictable.
